Published in Int J Mol Sci on June 19, 2015
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer | NCT05131243
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations. PLoS One (2016) 0.84
Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.79
Liquid biopsy in early stage lung cancer. Transl Lung Cancer Res (2016) 0.76
Level of circulated microRNA-421 in gastric carcinoma and related mechanisms. Int J Clin Exp Pathol (2015) 0.76
Circulating tumor DNA detection in lung cancer patients before and after surgery. Sci Rep (2016) 0.75
The feasibility of using mutation detection in ctDNA to assess tumor dynamics. Int J Cancer (2017) 0.75
Molecular predictive markers in tumors of the gastrointestinal tract. World J Gastrointest Oncol (2016) 0.75
The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing. Mol Diagn Ther (2017) 0.75
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Oncologist (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol (2014) 8.48
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol (2002) 7.17
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods (2006) 4.21
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13
Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 3.50
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28
Heterogeneity and cancer. Oncology (Williston Park) (2014) 2.89
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res (2011) 2.81
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol (2010) 2.54
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem (2013) 2.45
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol (2014) 2.14
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol (2015) 2.07
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem (2013) 1.62
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat (2010) 1.59
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol (2014) 1.57
Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol (1994) 1.55
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res (2012) 1.51
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J Natl Cancer Inst (2014) 1.50
Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol (2015) 1.48
Estimating mitotic activity in tumours. Histopathology (1996) 1.48
Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev (1994) 1.48
Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem (2014) 1.44
Does delay in fixation affect the number of mitotic figures in processed tissue? J Clin Pathol (1990) 1.38
Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat Diagn (2013) 1.37
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol (2014) 1.31
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol (2014) 1.28
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res (2014) 1.26
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev (2013) 1.23
Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet (2015) 1.21
Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One (2013) 1.19
Targeted therapy for melanoma: rational combinatorial approaches. Oncogene (2013) 1.18
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut (2015) 1.17
Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci (2008) 1.17
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer (2014) 1.14
Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. J Mol Diagn (2015) 1.14
Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res (2013) 1.10
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer (2010) 1.07
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J Clin Pathol (2014) 1.07
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med (2014) 1.06
Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol (2009) 1.05
Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer (2015) 1.03
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer (2013) 1.03
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn (2013) 1.02
Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 1.01
KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. Adv Anat Pathol (2010) 1.01
KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J Exp Clin Cancer Res (2014) 0.99
The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol (2014) 0.97
Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer (2014) 0.97
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol (2013) 0.96
Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Transl Oncol (2013) 0.95
Novel electrophoresis mechanism based on synchronous alternating drag perturbation. Electrophoresis (2005) 0.95
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer (2013) 0.94
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol (2011) 0.93
Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin Chem (2013) 0.93
EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int J Mol Sci (2013) 0.93
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat (2015) 0.91
Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial. J Clin Pathol (2014) 0.89
Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. Curr Oncol (2011) 0.89
Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol (2013) 0.87
Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma. Cancer Genomics Proteomics (2015) 0.86
BRAF mutation testing in colorectal cancer. Arch Pathol Lab Med (2010) 0.85
Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol (2014) 0.83
Somatic alterations as the basis for resistance to targeted therapies. J Pathol (2014) 0.83
Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol Rep (2013) 0.83
Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients. Cancer Biol Ther (2012) 0.83
Circulating tumor DNA: new horizons for improving cancer treatment. Future Oncol (2015) 0.83
Enhanced ratio of signals enables digital mutation scanning for rare allele detection. J Mol Diagn (2015) 0.82
Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann Diagn Pathol (2006) 0.81
PET/CT Imaging in Oncology: Exceptions That Prove the Rule. Case Rep Oncol Med (2013) 0.80
Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community? Cancer Treat Rev (2014) 0.78
Dynamic changes in numbers and properties of circulating tumor cells and their potential applications. Cancers (Basel) (2014) 0.76
Genomic imbalances in circulating DNA in Hodgkin's lymphoma. Lancet Haematol (2015) 0.76
Development and validation of a tetra-primer amplification refractory mutation system-polymerase chain reaction combined with melting analysis-assay for clinical JAK2 V617F mutation detection. Mol Diagn Ther (2014) 0.76
HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria. Appl Immunohistochem Mol Morphol (2015) 0.76